Corvus Pharmaceuticals, Inc. (CRVS): Total Liabilities
$9.91M
As of 2025-12-31
$13.95M
As of 2026-06-30
-6.5%
3-year compound annual growth
-5.8%
5-year compound annual growth
+10.1%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.91M | -72.7% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $36.34M | +429.0% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $6.87M | -43.3% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $12.12M | -1.4% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $12.29M | -8.1% | 2023-03-28, Balance as of period end |
| 2020-12-31 | $13.38M | +6.7% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $12.54M | +58.8% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $7.90M | -20.6% | 2020-03-09, Balance as of period end |
| 2017-12-31 | $9.94M | +35.3% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $7.35M | +94.4% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $3.78M | n/a | 2017-03-10, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $9.91M | -72.7% |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $27.81M | -17.2% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $44.59M | -16.7% |
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | $5.61M | -20.6% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $8.02M | +180.4% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $50.21M | +12.4% |
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $2.76M | -48.8% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
Compare CRVS, ALDX, HOWL, IXHL side by side · Screen every company in Pharmaceutical Preparations ↗